مباشر

FierceBiotechTravere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases Endpoints NewsMale contraception startup closes $92.5M Series B; Novartis bets on actinium Endpoints NewsTravere pays Everest $112M upfront to grow rare kidney disease pipeline Endpoints NewsLegend Biotech shares first in vivo CAR-T data, its next act after Carvykti FierceBiotechFulcrum scraps SCD program, considers options after FDA takes hard line on safety risks FierceBiotechASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push PharmaVoiceAs amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next BioWorldJanssen Pharmaceutica reports new TMEM175 activators BioWorldBlossomhill Therapeutics discovers new EGFR mutant inhibitors BioWorldChina Pharmaceutical University discloses new asiaticoside saponin compounds BioWorldWigen Biomedicine Technology patents new GTPase KRAS inhibitors LabiotechThe biggest biotech funding rounds in May 2026

FierceBiotech ٢ يونيو ٢٠٢٦

ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice

The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight agai...

The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP2 agents in triple-negative breast cancer.